8-K/A: Aixin Life International Restates 2021 Financials Following Accounting Review

Aixin Life International files an amended report to restate its 2021 and 2020 financial statements due to accounting errors related to acquisitions and capital contributions.

Summary

• Aixin Life International is filing an amended report to restate its consolidated financial statements for the fiscal year ended December 31, 2021, and the three and nine-month periods ended September 30, 2021.
• The restatement is due to the need to present the results of operations as if the acquisitions of Aixin Shangyan Hotel and Aixintang Pharmacies had occurred at the beginning of the period.
• The company also corrected the financial statement presentation for the capital contribution from Mr. Quanzhing Lin, its principal shareholder, during the year ended December 31, 2021.
• The restatement had no impact on the Total Stockholders Equity as restated at December 31, 2021, which was equal to the Total Stockholders equity as reported in the original 2021 Financial Statements.
• There was no impact on the results of the Company's operations in subsequent years, so no financial statements for periods ending after December 31, 2021, needed to be restated.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the restatement of financial statements, which indicates past accounting errors. However, the company is taking corrective action, which is a positive sign.

Positives

• The company is correcting its financial statements to provide a more accurate representation of its financial performance.
• The company's major shareholder, Mr. Lin, forgave a loan to the company for $2,473,228 during the year ended December 31, 2021, which was recorded as additional paid-in capital.
• The company's major shareholder made a capital contribution of $4,439,285 during the year ended December 31, 2021, which was recorded as additional paid-in capital.

Negatives

• The company is restating its financial statements due to accounting errors, which may raise concerns about the reliability of its financial reporting.
• The restatement resulted in a larger net loss for 2021 and a smaller net income for 2020.
• The company is involved in litigation related to a purchase agreement, which could result in financial losses.

Risks

• The company's operations are primarily in the PRC, which are subject to political, economic, and legal risks.
• The company's sales, purchases, and expenses are denominated in RMB, which is not freely convertible into foreign currencies.
• The company is involved in litigation, which could have a material adverse effect on its financial position, results of operations, or cash flows.
• The company's business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

Future Outlook

The company undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by applicable law.

Industry Context

The restatement highlights the importance of accurate financial reporting, especially for companies with international operations and complex transactions like acquisitions. It is common for companies, particularly smaller ones, to need to restate financials due to errors or changes in accounting standards.

Comparison to Industry Standards

• It is difficult to compare Aixin Life International's restatement directly to industry standards without knowing the specific details of the accounting errors and the company's industry peers.
• However, restatements are not uncommon, and the SEC requires companies to disclose material weaknesses in internal control over financial reporting.
• Comparable companies that have restated financials include Sino-Global Shipping America, Ltd. and Longtop Financial Technologies Limited, both of which faced scrutiny over their accounting practices.
• The impact of a restatement on a company's stock price and reputation can vary depending on the severity of the errors and the company's response.

Legal Proceedings

• The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment matters, and litigation regarding intellectual property rights.
• In December 2020, Jian Yiao (the Plaintiff) filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. (Aixintang Pharmacy, or the Defendant) in Zhangjiagang Peoples Court in Jiangsu Province.
• The complaint alleges that Jian Yiao is entitled to $ 392,305 (RMB 2,500,000 ) from Aixintang Pharmacy for not fulfilling the contractual obligation of a purchase agreement entered in March 2020 (the Purchase Agreement).
• Aixintang Pharmacy claimed that the Purchase Agreement was falsely entered by an employee through forged documents, and that Aixintang Pharmacy did not enter the Purchase Agreement.
• The Court determined that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products ordered and ordered Aixintang Pharmacy to pay $ 392,305 (RMB 2,500,000 ) to the Plaintiff.
• In December 2020, Aixintang Pharmacy filed a motion in the Jiangsu Suzhou Intermediate Peoples Court against the determination reached from the first trial.
• In February 2021, the judge in the Jiangsu Suzhou Intermediate Peoples Court denied the Defendants motion and upheld the judgment from the first trial.
• In March 2021, Aixintang Pharmacy filed another motion to the Jiangsu High Peoples Court on the basis that the Purchase Agreement was forged.
• In February 2022, Aixintang Pharmacy filed an appeal in Jiangsu High Peoples Court against the judgment reached by Jiangsu Suzhou Intermediate Peoples Court in February 2021.
• To date, this legal proceeding remains pending.
• In November 2021, the Company and Mr. Quanzhong Lin agreed that Mr. Lin shall assume any losses arising from this legal proceeding.

Related Party Transactions

• As of December 31, 2020, Aixin Shangyan Hotel had accounts receivable from an employee of AiXinZhonghong in the amount of $60,262.
• All the related party entities are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life).
• These advances to and from related parties were for working capital purpose, payable on demand, and bear no interest.
• Yirong Shen was a major shareholder of Aixin Shangyan Hotel prior to the closing of Hotel Purchase Agreement, and she serves as the supervisor of Aixin Shangyan Hotel.
• In May 2014, the Company entered a lease with its major shareholder for an office.
• During the year ended December 31, 2021, the Companys major shareholder Mr. Lin forgave his loan to the Company for $ 2,473,228 .
• During the year ended December 31, 2021, the Companys major shareholder made capital contribution to the Company in the amount of $ 4,439,285 .

Stakeholder Impact

• Shareholders: The restatement may negatively impact investor confidence and potentially the stock price.
• Employees: The restatement and potential financial impacts could affect employee morale and job security.
• Customers: The restatement is unlikely to directly impact customers.
• Suppliers: The restatement could affect the company's ability to pay suppliers in a timely manner.
• Creditors: The restatement could affect the company's creditworthiness and ability to obtain financing.

Key Dates

Keywords

restatement, financial statements, acquisitions, Aixin Life International, accounting, pharmacies, hotel, China